Pharmacoeconomic Analysis & Drug Utilization Review

The contract requires the performance of pharmacoeconomic analyses, drug utilization reviews, and cost-effectiveness modeling to inform pharmacy benefit decisions for MassHealth, leveraging clinical and claims data to evaluate the value and impact of pharmaceutical interventions. The work will support evidence-based programming and budgeting by assessing the economic implications of drug therapies, identifying patterns of use, and determining cost-effective treatment options within the state’s Medicaid program. All deliverables must align with public health objectives and regulatory standards governing pharmaceutical spending and patient outcomes. The opportunity is solicited as a subcontract under NAICS code 541611, with a response deadline of July 8, 2026, and is posted by the Massachusetts EHS01 agency. Performance is expected to occur in Boston, Massachusetts, with the primary focus on analyzing data to guide formulary and coverage decisions. There is no set-aside designation specified, and the contract is open to qualified subcontractors capable of delivering rigorous analytical services using real-world health data to meet the needs of a large-scale public health payer.